Advanced search
Publication Cover
Biomarkers Volume 28, 2023 - Issue 3
Submit an article Journal homepage
2,105
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)

Mattias Bergqvista Biovica International, Uppsala, SwedenCorrespondence[email protected]
View further author information
,
Adrian Nordmarka Biovica International, Uppsala, SwedenView further author information
,
Amy Williamsa Biovica International, Uppsala, SwedenView further author information
,
Costanza Paolettib University of Michigan Rogel Cancer Center, Ann Arbor, MI, USAView further author information
,
William Barlowc SWOG Statistical Center, Seattle, WA, USAView further author information
,
Erin F. Cobainb University of Michigan Rogel Cancer Center, Ann Arbor, MI, USAView further author information
,
Rita S. Mehtad Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA, USAView further author information
,
Julie R. Gralowe Seattle Cancer Care Alliance and University of Washington Medical Center, Seattle, WA, USAView further author information
,
Gabriel N. Hortobagyif Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USAView further author information
,
Kathy S. Albaing Loyola University Chicago Stritch School of Medicine, Maywood, IL, USAView further author information
,
Lajos Pusztaih Breast Medical Oncology, Yale School of Medicine, New Haven, CT, USAView further author information
,
Priyanka Sharmai Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USAView further author information
,
Andrew K. Godwinj Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA;View further author information
,
Alastair M. Thompsonk Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USAView further author information
,
Daniel F. Hayesb University of Michigan Rogel Cancer Center, Ann Arbor, MI, USAView further author information
&
James M. Raeb University of Michigan Rogel Cancer Center, Ann Arbor, MI, USAView further author information
 show all
Pages 313-322 | Received 21 Oct 2022, Accepted 07 Jan 2023, Published online: 29 Jan 2023

References

  • Bagegni, N., et al., 2017. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast cancer research, 19 (1), 123.
  • Bjöhle, J., et al., 2013. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast cancer research and treatment, 139 (3), 751–758.
  • Bonechi, M., et al., 2018. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget, 9 (23), 16389–16399.
  • Burstein, H.J., 2020. Systemic therapy for estrogen receptor-positive HER2-negative breast cancer. The new England journal of medicine, 383 (26), 2557–2570.
  • Cabel, L., et al., 2020. Plasma thymidine kinase 1 activity and outcome of ER + HER2– metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast cancer research, 22 (1), 98.
  • Carlson, R.W., et al., 2012. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. Journal of the national comprehensive cancer network, 10 (7), 821–829.
  • Gradishar, W.J., et al., 2017. NCCN guidelines insights: breast cancer, Version 1.2017. Journal of the national comprehensive cancer network, 15 (4), 433–451.
  • Hayes, D.F., 2021. Defining clinical utility of tumor biomarker tests: a clinician’s viewpoint. Journal of clinical oncology, 39 (3), 238–248.
  • Krishnamurthy, J., et al., 2022. A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. NPJ breast cancer, 8 (1), 35.
  • Larsson, A.M., et al., 2020. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. Scientific reports, 10 (1), 4484.
  • Malorni, L., et al., 2022. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European journal of cancer (Oxford, England: 1990), 164, 39–51.
  • McCartney, A., et al., 2019. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European journal of cancer (Oxford, England: 1990), 114, 55–66.
  • McCartney, A., et al., 2020. Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd Trial. Clinical cancer research, 26 (9), 2131–2139.
  • Mehta, R.S., et al., 2012. Combination anastrozole and fulvestrant in metastatic breast cancer. The new England journal of medicine, 367 (5), 435–444.
  • Mehta, R.S., et al., 2019. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. The new England journal of medicine, 380 (13), 1226–1234.
  • Merker, J.D., et al., 2018. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of clinical oncology, 36 (16), 1631–1641.
  • Paoletti, C., et al., 2021. Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial. Clinical cancer research, 27 (22), 6115–6123.
  • Robertson, J.F., et al., 1990. Thymidine kinase in breast cancer. British journal of cancer, 62 (4), 663–667.
  • Therasse, P., et al., 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the national cancer institute, 92 (3), 205–216.
  • Welin, M., et al ., 2004. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proceedings of the national academy of sciences, USA, 101: 17970–17975.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.